

11. Literaturverzeichnis

1. Robert Koch-Institut. 2002.
2. Deutsche Gesellschaft für Senologie, *Brustkrebsfrüherkennung in Deutschland - Konsensusberichte*. 2000.
3. Beckmann, M., *Genetische Risikofaktoren des Mammakarzinoms*. Gynäkologe, 2002. **35**: p. 527-536.
4. Froster, U. and M.B. Robbiani, *Genetische Abklärung beim Mammakarzinom - Was muß der Praktiker wissen? hautnah gynäkologie*, 1996.
5. Krebsregister, S., *Morbidität und Mortalität an Bösartigen Neubildungen im Saarland 1994 und 1995. Jahresbericht des Saarländischen Krebsregisters, Sonderheft des Statistischen Landesamtes Saarland Nr. 191, 1998*. 1998.
6. NIH, *National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up*. Gynecol Oncol, 1994. **55**(3 Pt 2): p. S4-14.
7. American cancer society, *Cancer Reference Information, in The American cancer society*. 2002.
8. Scharf, A., H. Günter, and C. Sohn, *Screening auf Ovarialkarzinom*. Gynäkologe, 2002. **35**: p. 537-547.
9. Newman, B., et al., *Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families*. Proc Natl Acad Sci U S A, 1988. **85**(9): p. 3044-8.
10. Schmutzler, R.K., et al., *[Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma]*. Dtsch Med Wochenschr, 1999. **124**(18): p. 563-6.
11. Eisinger, F., et al., *Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee*. Ann Oncol, 1998. **9**(9): p. 939-50.
12. Claus, E.B., N. Risch, and W.D. Thompson, *Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction*. Cancer, 1994. **73**(3): p. 643-51.
13. Chang-Claude, J., et al., *[Risk assessment for familial occurrence of breast cancer]*. Zentralbl Gynakol, 1995. **117**(8): p. 423-34.
14. Claus, E.B., N.J. Risch, and W.D. Thompson, *Age at onset as an indicator of familial risk of breast cancer*. Am J Epidemiol, 1990. **131**(6): p. 961-72.
15. Kelsey, J.L. and G.S. Berkowitz, *Breast cancer epidemiology*. Cancer Res, 1988. **48**(20): p. 5615-23.
16. Deutsche Krebshilfe, *Eierstockkrebs*. 2000.
17. Seitz, S., et al., *Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families*. Oncogene, 1997. **14**(6): p. 741-3.
18. Serova, O.M., et al., *Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?* Am J Hum Genet, 1997. **60**(3): p. 486-95.
19. Smith, S.A., et al., *Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome*. Nat Genet, 1992. **2**(2): p. 128-31.
20. Weitzel, *Genetics and hereditary breast and ovarian carcinoma*. American society of Hematology, 1999.

21. Ford, D., et al., *Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.* Lancet, 1994. **343**(8899): p. 692-5.
22. Easton, D.F., D. Ford, and D.T. Bishop, *Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.* Am J Hum Genet, 1995. **56**(1): p. 265-71.
23. Struewing, J.P., et al., *The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.* N Engl J Med, 1997. **336**(20): p. 1401-8.
24. Breast Cancer Linkage Consortium, *Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases.* Breast Cancer Linkage Consortium. Lancet, 1997. **349**(9064): p. 1505-10.
25. Marcus, J.N., et al., *Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage.* Cancer, 1996. **77**(4): p. 697-709.
26. Brekelmans, C.T., et al., *Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.* J Clin Oncol, 2001. **19**(4): p. 924-30.
27. Schildkraut, J.M., N. Risch, and W.D. Thompson, *Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship.* Am J Hum Genet, 1989. **45**(4): p. 521-9.
28. Miki, Y., et al., *A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.* Science, 1994. **266**(5182): p. 66-71.
29. Hall, J.M., et al., *Linkage of early-onset familial breast cancer to chromosome 17q21.* Science, 1990. **250**(4988): p. 1684-9.
30. Narod, S.A., et al., *Familial breast-ovarian cancer locus on chromosome 17q12-q23.* Lancet, 1991. **338**(8759): p. 82-3.
31. Easton, D.F., et al., *Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.* Am J Hum Genet, 1993. **52**(4): p. 678-701.
32. Ford, D., D.F. Easton, and J. Peto, *Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.* Am J Hum Genet, 1995. **57**(6): p. 1457-62.
33. Narod, S.A., et al., *An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium.* Am J Hum Genet, 1995. **56**(1): p. 254-64.
34. Wooster, R., et al., *Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.* Science, 1994. **265**(5181): p. 2088-90.
35. Tavtigian, S.V., et al., *The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.* Nat Genet, 1996. **12**(3): p. 333-7.
36. Gayther, S.A., et al., *Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.* Nat Genet, 1997. **15**(1): p. 103-5.
37. Stratton, M.R., *Recent advances in understanding of genetic susceptibility to breast cancer.* Hum Mol Genet, 1996. **5**(Spec No): p. 1515-9.
38. Vasen, H.F., *Screening in breast cancer families: is it useful?* Ann Med, 1994. **26**(3): p. 185-90.
39. Tilanus-Linthorst, M.M., et al., *Earlier detection of breast cancer by surveillance of women at familial risk.* Eur J Cancer, 2000. **36**(4): p. 514-9.
40. Armstrong, K. and B.L. Weber, *Breast cancer screening for high-risk women: too little, too late?* J Clin Oncol, 2001. **19**(4): p. 919-20.

41. Tabar, L., et al., *Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial*. *Cancer*, 1995. **75**(10): p. 2507-17.
42. Schwartz, P.E., *Nongenetic screening of ovarian malignancies*. *Obstet Gynecol Clin North Am*, 2001. **28**(4): p. 637-51, vii.
43. MacDonald, N.D., A.N. Rosenthal, and I.J. Jacobs, *Screening for ovarian cancer*. *Ann Acad Med Singapore*, 1998. **27**(5): p. 676-82.
44. Hartmann, L.C., et al., *Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer*. *N Engl J Med*, 1999. **340**(2): p. 77-84.
45. Temple, W.J., et al., *Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer*. *Am J Surg*, 1991. **161**(4): p. 413-5.
46. NIH, *NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer*. *JAMA*, 1995. **273**(6): p. 491-7.
47. Rebbeck, T.R., et al., *Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers*. *J Natl Cancer Inst*, 1999. **91**(17): p. 1475-9.
48. Rebbeck, T.R., *Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers*. *Eur J Cancer*, 2002. **38 Suppl 6**: p. S15-7.
49. Kiechle, M. and R. Schmutzler, *Präventive Strategien bei familiärer Brustkrebsprädisposition*. *Radiologe*, 2001. **41**(4): p. 366-70.
50. Fisher, B., et al., *Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study*. *J Natl Cancer Inst*, 1998. **90**(18): p. 1371-88.
51. Powles, T., et al., *Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial*. *Lancet*, 1998. **352**(9122): p. 98-101.
52. Veronesi, U., et al., *Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study*. *Lancet*, 1998. **352**(9122): p. 93-7.
53. Gail, M.H., et al., *Projecting individualized probabilities of developing breast cancer for white females who are being examined annually*. *J Natl Cancer Inst*, 1989. **81**(24): p. 1879-86.
54. Paepke, S., et al., *[Chemoprevention of breast cancer: a literature review and report on the current status in Germany]*. *Zentralbl Gynakol*, 2003. **125**(9): p. 338-45.
55. Casagrande, J.T., et al., *"Incessant ovulation" and ovarian cancer*. *Lancet*, 1979. **2**(8135): p. 170-3.
56. Mori, M., et al., *Reproductive, genetic, and dietary risk factors for ovarian cancer*. *Am J Epidemiol*, 1988. **128**(4): p. 771-7.
57. Hildreth, N.G., et al., *An epidemiologic study of epithelial carcinoma of the ovary*. *Am J Epidemiol*, 1981. **114**(3): p. 398-405.
58. Centers for Disease Control and the National Institute of Child Health and Human Development, *The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development*. *N Engl J Med*, 1987. **316**(11): p. 650-5.
59. Narod, S.A., et al., *Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group*. *N Engl J Med*, 1998. **339**(7): p. 424-8.

60. Schmutzler, R., M. Beckmann, and M. Kiechle, *Familiäres Mamma- und Ovarialkarzinom - Vorschlag für ein strukturiertes Früherkennungsprogramm*. Deutsches Ärzteblatt, 2002. **20**: p. 1372-1378.
61. Thomas, D.B., et al., *Randomized trial of breast self-examination in Shanghai: methodology and preliminary results*. J Natl Cancer Inst, 1997. **89**(5): p. 355-65.
62. Burke, W., et al., *Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium*. JAMA, 1997. **277**(12): p. 997-1003.
63. American Cancer Society Breast Cancer Detection Demonstration Projects, *Report of the Working Group to Review the National Cancer Institute- American Cancer Society Breast Cancer Detection Demonstration Projects*. J Natl Cancer Inst, 1979. **62**(3): p. 639-709.
64. Miller, A.B., C.J. Baines, and C. Turnbull, *The role of the nurse-examiner in the National Breast Screening Study*. Can J Public Health, 1991. **82**(3): p. 162-7.
65. Fletcher, S.W., M.S. O'Malley, and L.A. Bunce, *Physicians' abilities to detect lumps in silicone breast models*. JAMA, 1985. **253**(15): p. 2224-8.
66. Campbell, H.S., et al., *Improving physicians' and nurses' clinical breast examination: a randomized controlled trial*. Am J Prev Med, 1991. **7**(1): p. 1-8.
67. Hendrick, R.E., et al., *Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials*. J Natl Cancer Inst Monogr, 1997. **22**: p. 87-92.
68. Tabar, L., et al., *Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare*. Lancet, 1985. **1**(8433): p. 829-32.
69. Robertson, C.L., *A private breast imaging practice: medical audit of 25,788 screening and 1,077 diagnostic examinations*. Radiology, 1993. **187**(1): p. 75-9.
70. Burhenne, H.J., et al., *Interval breast cancers in the Screening Mammography Program of British Columbia: analysis and classification*. AJR Am J Roentgenol, 1994. **162**(5): p. 1067-71; discussion 1072-5.
71. Schreer, I., *Auswertung der bisherigen Mammographie-Screening-Studien in Europa und in Nordamerika*. Radiologe, 2001. **41**(4): p. 344-51.
72. Moskowitz, M., *Guidelines for screening for breast cancer. Is a revision in order?* Radiol Clin North Am, 1992. **30**(1): p. 221-33.
73. Feig, S.A., *Increased benefit from shorter screening mammography intervals for women ages 40-49 years*. Cancer, 1997. **80**(11): p. 2035-9.
74. Brekelmans, C.T., et al., *Breast cancer after a negative screen: follow-up of women participating in the DOM Screening Programme*. Eur J Cancer, 1992: p. 893-5.
75. Kerlikowske, K., et al., *Effect of age, breast density, and family history on the sensitivity of first screening mammography*. JAMA, 1996. **276**(1): p. 33-8.
76. Ren, J.J. and P.G. Peer, *A study on effectiveness of screening mammograms*. Int J Epidemiol, 2000. **29**(5): p. 803-6.
77. Tabar, L., et al., *Tumour development, histology and grade of breast cancers: prognosis and progression*. Int J Cancer, 1996. **66**(4): p. 413-9.
78. Tabar, L., et al., *The natural history of breast carcinoma: what have we learned from screening?* Cancer, 1999. **86**(3): p. 449-62.
79. Bjurstam, N., et al., *The Gothenburg Breast Cancer Screening Trial: preliminary*

- results on breast cancer mortality for women aged 39-49.* J Natl Cancer Inst Monogr, 1997. **22**: p. 53-5.
80. Andersson, I. and L. Janzon, *Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program.* J Natl Cancer Inst Monogr, 1997. **22**: p. 63-7.
 81. Liberman, L., et al., *Screening mammography: value in women 35-39 years old.* AJR Am J Roentgenol, 1993. **161**(1): p. 53-6.
 82. Lesnick, G.J., *Detection of breast cancer in young women.* JAMA, 1977. **237**(10): p. 967-9.
 83. Yelland, A., et al., *Diagnosing breast carcinoma in young women.* BMJ, 1991. **302**(6777): p. 618-20.
 84. Beck, L., *Bildgebende Verfahren negativ, Brustkrebs zu spät erkannt.* Gynäkologe, 2002. **35**: p. 593-594.
 85. Dodd, G.D., *Present status of thermography, ultrasound and mammography in breast cancer detection.* Cancer, 1977. **39**(6 Suppl): p. 2796-805.
 86. Durfee, S.M., et al., *Sonographic Evaluation of Clinically Palpable Breast Cancers Invisible on Mammography.* Breast J, 2000. **6**(4): p. 247-251.
 87. Blohmer, J.U., et al., *Comparison of various imaging methods with particular evaluation of color Doppler sonography for planning surgery for breast tumors.* Arch Gynecol Obstet, 1999. **262**(3-4): p. 159-71.
 88. Heywang-Kobrunner, S.H., et al., *International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions.* Eur Radiol, 2001. **11**(4): p. 531-46.
 89. Kriege, M., et al., *Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.* N Engl J Med, 2004. **351**(5): p. 427-37.
 90. Warner, E., et al., *Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.* J Clin Oncol, 2001. **19**(15): p. 3524-31.
 91. Bone, B., et al., *Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions.* Acta Radiol, 1997. **38**(4 Pt 1): p. 489-96.
 92. Heywang-Kobrunner, S.H., et al., *Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions.* Eur J Radiol, 1997. **24**(2): p. 94-108.
 93. Obdeijn, I.M., et al., *MR lesion detection in a breast cancer population.* J Magn Reson Imaging, 1996. **6**(6): p. 849-54.
 94. Kacal, G.M., et al., *Detection of breast cancer with conventional mammography and contrast-enhanced MR imaging.* Eur Radiol, 1998. **8**(2): p. 194-200.
 95. Davis, P.L. and K.S. McCarty, Jr., *Sensitivity of enhanced MRI for the detection of breast cancer: new, multicentric, residual, and recurrent.* Eur Radiol, 1997. **7**(Suppl 5): p. 289-98.
 96. Tilanus-Linthorst, M.M., et al., *First experiences in screening women at high risk for breast cancer with MR imaging.* Breast Cancer Res Treat, 2000. **63**(1): p. 53-60.
 97. Westerhof, J.P., et al., *MR imaging of mammographically detected clustered microcalcifications: is there any value?* Radiology, 1998. **207**(3): p. 675-81.
 98. Pschyrembel, 1990. **256**: p. 1850.

99. Bast, R.C., Jr., et al., *A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.* N Engl J Med, 1983. **309**(15): p. 883-7.
100. Dorum, A., et al., *Early detection of familial ovarian cancer.* Eur J Cancer, 1996. **32A**(10): p. 1645-51.
101. Mann, W.J., et al., *Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma.* J Natl Cancer Inst, 1988. **80**(3): p. 208-9.
102. Jacobs, I. and R.C. Bast, Jr., *The CA 125 tumour-associated antigen: a review of the literature.* Hum Reprod, 1989. **4**(1): p. 1-12.
103. Higgins, R.V., et al., *Interobserver variation in ovarian measurements using transvaginal sonography.* Gynecol Oncol, 1990. **39**(1): p. 69-71.
104. Rodriguez, M.H., et al., *The use of transvaginal sonography for evaluation of postmenopausal ovarian size and morphology.* Am J Obstet Gynecol, 1988. **159**(4): p. 810-4.
105. Zanotti, K.M. and A.W. Kennedy, *Screening for gynecologic cancer.* Med Clin North Am, 1999. **83**(6): p. 1467-87.
106. Hogg, R. and M. Friedlander, *Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.* J Clin Oncol, 2004. **22**(7): p. 1315-27.
107. Neise, C., *Familiäre Brustkrebsbelastung und Vorsorgeverhalten - Akzeptanz diagnostischer Möglichkeiten zur Früherkennung von Brustkrebs und psychosoziale Aspekte des Vorsorgeverhaltens von Frauen mit familiärer Mammakarzinombelastung, Dissertation.* 1999, Institut für Sexualwissenschaften/Sexualmedizin und der Klinik für Gynäkologie und Geburtshilfe der Medizinischen Fakultät Charite der Humboldt-Universität zu Berlin: Berlin.
108. Albert, U.S. and K.D. Schulz, *Short version of the Guideline: Early Detection of Breast Cancer in Germany. An evidence-, consensus-, and outcome-based guideline according to the German Association of the Scientific Medical Societies (AWMF) and the German Agency for Quality in Medicine (AeZQ).* J Cancer Res Clin Oncol, 2004. **130**(9): p. 527-36.
109. Kash, K.M., et al., *Psychological distress and surveillance behaviors of women with a family history of breast cancer.* J Natl Cancer Inst, 1992. **84**(1): p. 24-30.
110. Alagna, S.W., et al., *Performance of breast self-examination by women at high risk for breast cancer.* Women Health, 1987. **12**(2): p. 29-46.
111. Lerman, C., et al., *Factors associated with repeat adherence to breast cancer screening.* Prev Med, 1990. **19**(3): p. 279-90.
112. Carty, N.J., et al., *Management of fibroadenoma of the breast.* Ann R Coll Surg Engl, 1995. **77**(2): p. 127-30.
113. Delorme, S., *Mammasonographie und Magnetresonanz-Mammographie als ergänzende Methoden im Mammographiescreening.* Radiologe, 2001. **41**(4): p. 371-8.
114. Schelling, M., et al., *Optimized differential diagnosis of breast lesions by combined B-mode and color Doppler sonography.* Ultrasound Obstet Gynecol, 1997. **10**(1): p. 48-53.
115. Marquet, K.L., et al., *[Displacement margins and edge contour: informative criteria of tumor dignity in ultrasound mammography].* Geburtshilfe Frauenheilkd, 1995. **55**(10): p. 548-52.
116. Mettler, F.A., et al., *Benefits versus risks from mammography: a critical reassessment.* Cancer, 1996. **77**(5): p. 903-9.

117. Evans, J.S., J.E. Wennberg, and B.J. McNeil, *The influence of diagnostic radiography on the incidence of breast cancer and leukemia*. N Engl J Med, 1986. **315**(13): p. 810-5.
118. Gohagan, J.K., et al., *Radiogenic breast cancer effects of mammographic screening*. J Natl Cancer Inst, 1986. **77**(1): p. 71-6.
119. Jung, H., [*Mammography and radiation risk*]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr, 1998. **169**(4): p. 336- 43.
120. Elmore, J.G., et al., *Ten-year risk of false positive screening mammograms and clinical breast examinations*. N Engl J Med, 1998. **338**(16): p. 1089-96.
121. Christiansen, C.L., et al., *Predicting the cumulative risk of false-positive mammograms*. J Natl Cancer Inst, 2000. **92**(20): p. 1657-66.
122. Barton, M.B., R. Harris, and S.W. Fletcher, *The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?* JAMA, 1999. **282**(13): p. 1270-80.
123. Albert, U. and K. Schulz. *Selbstuntersuchung der Brust*. in *Manual I zur Stufe-3-Leitlinien Konsensuskonferenz: Brustkrebs-Früherkennung in Deutschland*. 2002. Wissenschaftszentrum Bonn.
124. Harvey, B.J., et al., *Effect of breast self-examination techniques on the risk of death from breast cancer*. Cmaj, 1997. **157**(9): p. 1205-12.
125. Segura, J.M., et al., *Utilization of screening mammography as a preventive practice prior to initiating a population-based breast cancer screening program*. J Clin Epidemiol, 2000. **53**(6): p. 595-603.
126. Gastrin, G., et al., *Incidence and mortality from breast cancer in the Mamma Program for Breast Screening in Finland, 1973-1986*. Cancer, 1994. **73**(8): p. 2168-74.
127. Baines, C.J. and T. To, *Changes in breast self-examination behavior achieved by 89,835 participants in the Canadian National Breast Screening Study*. Cancer, 1990. **66**(3): p. 570-6.
128. Korn, J., *The clinical breast examination: still important*. The Medical Journal of Allina, 1998. **7**(2).
129. Kreienberg, R. *Klinische Brustuntersuchung*. in *Manual I zur Stufe-3-Leitlinien Konsensuskonferenz: Brustkrebs-Früherkennung in Deutschland*. 2002. Wissenschaftszentrum Bonn.
130. Kuhl, C.K., et al., *Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results*. Radiology, 2000. **215**(1): p. 267-79.
131. Bick, U., [*An integrated early detection concept in women with a genetic predisposition for breast cancer*]. Radiologe, 1997. **37**(8): p. 591-6.
132. Heywang-Köbrunner, S. and H. Altland. *MRT: Bildgebende Verfahren der Früherkennung*. in *Manual I zur Stufe-3-Leitlinien Konsensuskonferenz: Brustkrebs-Früherkennung in Deutschland*. 2002. Wissenschaftszentrum Bonn.
133. Muller-Schimpfle, M., et al., *Do mammography, sonography, and MR mammography have a diagnostic benefit compared with mammography and sonography?* AJR Am J Roentgenol, 1997. **168**(5): p. 1323-9.
134. Kaufmann, M., et al., *Empfehlungen für eine standardisierte Diagnostik, Therapie und Nachsorge - Das Ovarialkarzinom*. 1996, Tumorzentrum Heidelberg / Mannheim: Heidelberg/ Mannheim.
135. Schelling, M. and J. de Waal, *Maligne Ovarialtumoren - Früherkennung*. 2001,

- Tumorzentrum München: München. p. 10-13.
136. Wilke, I., *Screening beim Ovarialkarzinom - aktueller Stand und Aussichten*, in *Frauenklinik- Info Dezember 1996*. 1996: Jena.
 137. Bell, R., M. Petticrew, and T. Sheldon, *The performance of screening tests for ovarian cancer: results of a systematic review*. *Br J Obstet Gynaecol*, 1998. **105**(11): p. 1136-47.
 138. Evans, D.G., et al., *The impact of genetic counselling on risk perception in women with a family history of breast cancer*. *Br J Cancer*, 1994. **70**(5): p. 934-8.
 139. Kash, K.M., et al., *Psychological counseling strategies for women at risk of breast cancer*. *J Natl Cancer Inst Monogr*, 1995. **17**: p. 73-9.
 140. Lloyd, S., et al., *Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling*. *Br J Cancer*, 1996. **74**(3): p. 482-7.
 141. Payne, D.K., M.D. Sullivan, and M.J. Massie, *Women's psychological reactions to breast cancer*. *Semin Oncol*, 1996. **23**(1 Suppl 2): p. 89-97.
 142. Baum, A., A.L. Friedman, and S.G. Zakowski, *Stress and genetic testing for disease risk*. *Health Psychol*, 1997. **16**(1): p. 8-19.
 143. Hofferbert, S., et al., *Simultaneous interdisciplinary counseling in German breast/ovarian cancer families: first experiences with patient perceptions, surveillance behavior and acceptance of genetic testing*. *Genet Couns*, 2000. **11**(2): p. 127-46.
 144. Weinstein, N.D. and W.M. Klein, *Resistance of personal risk perceptions to debiasing interventions*. *Health Psychol*, 1995. **14**(2): p. 132-40.
 145. Cannistra, S.A., *Cancer of the ovary*. *N Engl J Med*, 1993. **329**(21): p. 1550-9.

[1-145]